Navigation Links
Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
Date:10/5/2009

CHENGDU, China, Oct. 5 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co. Inc. (NYSE Amex: TPI), a developer, manufacturer and supplier of modernized traditional Chinese medicine ("TCM") and generic pharmaceuticals in China, today declared a quarterly cash dividend to be paid to its common stock shareholders. The dividend of $0.025 will be paid to shareholders of record as of October 30, 2009, with the actual distribution occurring on or about December 10, 2009.

In addition, Tianyin is now eligible to become an S-3 filer which is reserved for companies on a listed exchange that have filed all required reports on a timely basis during the past twelve months. This allows automatic updating of disclosure requirements with the 10-K or 10-Q filings and significantly reduces the costs and resource burdens on the company associated with filing post-effective amendments to the registration statement.

Dr. Jiang Guoqing, Tianyin's Chairman and Chief Executive Officer, commented, "We appreciate the continued support of our shareholders and believe that our strategy of providing a current return and potential capital appreciation resonates well with investors who are looking for growth and income. In addition, this S-3 eligibility will save the company money and resources to meet its filing requirements."

About Tianyin Pharmaceuticals

Tianyin is a manufacturer and supplier of modernized Traditional Chinese Medicine ("TCM") in China. It was established in 1994 and acquired by the current management team in August 2003. It has a comprehensive product portfolio of 39 products, 22 of which are listed in the highly selective National Medicine Catalog of the National Medical Insurance program. Tianyin owns and operates two GMP manufacturing facilities and an R&D platform supported by leading Chinese academic institutions. The Company has a pipeline of 17 pharmaceutical products pending approval. Tianyin has an extensive nationwide distribution network throughout China with a sales force of 720 salespeople. Tianyin is headquartered in Chengdu, Sichuan Province with two manufacturing facilities and a total of 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com.

Safe Harbor Statement

The Statements which are not historical facts during the presentation are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.


    For more information, please contact:

    For the Company:
    Allen Tang, Ph.D., MBA, Assistant to the CEO in China
    Tel: +86-158-2122-5642
    Email: Allen.y.tang@gmail.com

    Investors:
    Mr. Matthew Hayden, HC International
    Tel: +1-561-245-5155
    Email: matt.hayden@hcinternational.net
    Web: http://www.hcinternational.net

SOURCE Tianyin Pharmaceutical Co. Inc.


'/>"/>
SOURCE Tianyin Pharmaceutical Co. Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... , May 5, 2017  Hill-Rom Holdings, Inc. ... add approximately 100,000 square feet to its Welch Allyn ... 2016 its commitment to bring more than 100 new ... where Welch Allyn has maintained a significant presence for ... accommodate these new positions, a large portion of which ...
(Date:5/4/2017)... DIEGO , May 4, 2017 ... demonstrating its wireless, handheld ultrasound scanners this week ... Annual Scientific Meeting (ACOG) in San ... "Clarius is the perfect tool ... growth and heart rate, and evaluate pregnancy-related complications ...
(Date:5/4/2017)... , May 4, 2017  A new tight-tolerance ... and other highly-engineered materials, is being launched by ... has been developed in recent years to service ... and surgical applications. More expensive materials such as ... microextrusion tubing due to their ability to consistently ...
Breaking Medicine Technology:
(Date:5/27/2017)... ... May 27, 2017 , ... Most us are familiar ... a new study from the Osteoarthritis Initiative shows that certain people who ... Knowing this in advance may give doctors the opportunity to treat patients before the ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... gather at Boston CEO 2017 on May 30th and 31st at The Four ... forum for leading executives in the life sciences, offering exclusive access to key ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, a leading provider ... monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI is a sleep ... With this platform, initializing devices and importing studies are just one-click operations. This ...
(Date:5/26/2017)... ... 2017 , ... via seating is proud to partner with ... specifically designed for clinical areas. Genie Copper Mesh is a crossover chair for ... provide customers with a game changing chair that is affordably priced,” Chas Hepler ...
(Date:5/26/2017)... ... 26, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... on the Peace Agreements being discussed by President Donald Trump and the rest of ... try to speed up peace talks in the continuous battle between Israel and Palestine. ...
Breaking Medicine News(10 mins):